Sitaxentan (sodium salt)

Sitaxentan is a potent nonpeptide endothelin A (ETA) receptor antagonist (IC50 = 1.4 nM). It is selective for ETA over ETB receptors (IC50 = 9,800 nM). Sitaxentan inhibits phosphoinositol hydrolysis induced by endothelin-1 (Cay-24127) in COS-7 cells (pA2 = 8). In vivo, sitaxentan reduces blood pressure in a rat model of acute hypoxia-induced pulmonary hypertension (ED50 = 0.5 mg/kg). It reduces femoral artery neointimal lesion size in a mouse model of intraluminal injury. Sitaxentan (15 mg/kg) decreases bronchoalveolar lavage fluid (BALF) pleocytosis, as well as pulmonary collagen deposition and fibrosis, and improves lung mechanics in a mouse model of bleomycin-induced lung injury. Formulations containing sitaxentan have been used in the treatment of hypertension.Formal Name: N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-(6-methyl-1,3-benzodioxol-5-yl)acetyl]-3-thiophenesulfonamide, monosodium salt. CAS Number: 210421-74-2. Synonyms: TBC 11251, Thelin. Molecular Formula: C18H14ClN2O6S2 . Na. Formula Weight: 476.9. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMF: 10mg/mL, DMSO: 15mg/mL, DMSO:PBS (pH 7.2) (1:6): 0.14mg/mL, Ethanol: 5mg/mL. lambdamax: 266 nm. SMILES: CC1=C(CC(C2=C(S([N-]C3=C(Cl)C(C)=NO3)(=O)=O)C=CS2)=O)C=C4C(OCO4)=C1.[Na+]. InChi Code: InChI=1S/C18H14ClN2O6S2.Na/c1-9-5-13-14(26-8-25-13)7-11(9)6-12(22)17-15(3-4-28-17)29(23,24)21-18-16(19)10(2)20-27-18,/h3-5,7H,6,8H2,1-2H3,/q-1,+1. InChi Key: MDTNUYUCUYPIHE-UHFFFAOYSA-N.